MedTrace Logo

A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT07540442 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-04-20

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

MG-K10 Injection (Humanized Monoclonal Antibody)

loading dose (SC) at Week 0, followed by a single dose Q2W through Week 52

DRUG

Placebo for MG-K10

Initial loading dose (SC), then single dose Q2W through Week 52

Sponsors & Collaborators

  • Shanghai Mabgeek Biotech.Co.Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-17
Primary Completion
2027-01-05
Completion
2027-11-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07540442 on ClinicalTrials.gov